Atrial Fibrillation
Wednesday, May 29th, 2013
CIRCULATIONAHA: May 22, 2013 Background—Percutaneous left atrial appendage (LAA) occlusion and novel pharmacological therapies are now available to manage stroke risk in patients with non-valvular atrial fibrillation (NVAF). However, the cost effectiveness of LAA occlusion compared to dabigatran and warfarin in patients with NVAF is unknown. Methods and Results—Cost-utility analysis using a patient level Markov micro-simulation […]
Atrial Fibrillation
Wednesday, May 29th, 2013
CIRCEP: May 17, 2013 Background—Superior vena cava (SVC) is an infrequent yet an important source of atrial fibrillation (AF). The clinical impact of adenosine triphosphate (ATP) injection on arrhythmogenic SVC has not been evaluated. Methods and Results—43 patients (59 ± 11 years; 32 males) who underwent ATP test for arrhythmogenic SVC after the electrical isolation at […]
Atrial Fibrillation
Wednesday, May 29th, 2013
CIRCEP: May 16, 2013 Background—Implantable cardioverter-defibrillators (ICDs), the first-line of therapy for preventing sudden cardiac death in high-risk patients, deliver “appropriate” shocks for termination of ventricular tachycardia/fibrillation (VT/VF). A common shortcoming of ICDs is imperfect rhythm discrimination, resulting in the delivery of “inappropriate” shocks for atrial fibrillation (AF). An underexplored area for rhythm discrimination is the […]
Atrial Fibrillation
Wednesday, May 29th, 2013
Chest Journal: May 9, 2013 Background When oral anticoagulation (OAC) with adjusted dose Vitamin K antagonist (VKA,) is used, the quality of anticoagulation control (as reflected by time in therapeutic range (TTR) of the International Normalised Ratio, INR) is an important determinant of thromboembolism and bleeding. Our objective was to derive a validated scheme using patient-related clinical parameters for […]
Atrial Fibrillation
Wednesday, May 29th, 2013
Circulation Journal: May 9, 2013 Atrial fibrillation (AF) is a major risk factor for stroke and the prevalence increases with age. Oral anticoagulants (OACs) are effective, but underused in elderly patients, primarily because of concerns about bleeding. Clinical study data on the efficacy (stroke/systemic embolism) and safety (bleeding events) of OACs in elderly patients with […]
Clinical Trials
Wednesday, May 29th, 2013
JACC: May 28, 2013 Post-operative atrial fibrillation (PoAF) is among the most common complications of cardiac surgery and substantially increases morbidity and healthcare costs. Despite decades of surgical, anesthetic, and medical advances, rates of PoAF remain largely unchanged. Experiments and animal models suggest that perioperative fish oil (omega-3 fatty acids) may reduce PoAF (1). We […]
Clinical Trials
Wednesday, May 29th, 2013
International Journal of Stroke: May 22, 2013 Background It remains controversial whether dual antiplatelet therapy reduces stroke more than aspirin alone. Aim We aimed to assess the effects of adding clopidogrel to aspirin on the occurrence of stroke and major haemorrhage in patients with vascular disease. Methods Meta-analysis of published randomized trials comparing the combination […]
Clinical Trials
Wednesday, May 29th, 2013
STROKEAHA: May 21, 2013 Background and Purpose—There is a temporal relationship between cannabis use and stroke in case series and population-based studies. Methods—Consecutive stroke patients, aged 18 to 55 years, who had urine screens for cannabis were compared with a cohort of control patients admitted to hospital without cardiovascular or neurological diagnoses. Read more
Clinical Trials
Wednesday, May 29th, 2013
International Journal of Stroke: May 20, 2013 Several landmark clinical trials of endovascular therapy for acute ischemic stroke have recently jolted the concerted multidisciplinary efforts to develop effective revascularization strategies. Further consideration of these four endovascular stroke trials published in the last year suggests a more fundamental question: are these trials of specific treatments or […]
Clinical Trials
Wednesday, May 29th, 2013
International Journal of Cardiology: May 10, 2013 Background Anticoagulation is recommended in patients with atrial fibrillation (AF) to prevent strokes. Vitamin K antagonists, such as warfarin, are associated with numerous practical limitations – frequent anticoagulation monitoring, lifestyle and dietary restrictions – that complicate patient management and may impact health-related quality of life (HRQoL). This study […]
